Immunotherapy in Combination with Chemotherapy for Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks estrogen and progesterone receptors and does not overexpress the human epidermal growth factor receptor 2 (HER2). Previous treatment options for TNBC were limited to chemotherapy alone, resulting in a poor pati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Otros Autores:	Meléndez-Solano, Elizabeth, Chapa, Christian, Stevens Barrón, Jazmín Cristina
Formato:	Artículo
Lenguaje:	en_US
Publicado:	2023
Materias:	Cancer breast triple negative breast cancer immunotherapy efficacy safety atezolizumab camrelizumab paclitaxel gemcitabine info:eu-repo/classification/cti/2 info:eu-repo/classification/cti/3
Acceso en línea:	https://doi.org/10.2174/1389557523666230517152538 https://pubmed.ncbi.nlm.nih.gov/37198990/
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Immunotherapy in Combination with Chemotherapy for Triple-Negative Breast Cancer

Ejemplares similares